



Original Research

Feasibility and Safety of a Home-based Electroencephalogram Neurofeedback Intervention to Reduce Chronic Neuropathic Pain: A Cohort Clinical Trial



Mohamed Sakel, MBBS ^a, Karen Saunders, BSc (Hons) ^b,
Christine Ozolins, MSc ^c, Riya Biswas, PhD ^c

^a Neuro-rehabilitation Department, East Kent Hospitals University NHS Foundation Trust, UK

^b Centre for Health Services Studies, University of Kent, Kent, UK

^c Exsurgo Ltd, Auckland, New Zealand

KEYWORDS

Brain computer interface;
Chronic neuropathic pain;
Feasibility;
Home-based neurofeedback;
Rehabilitation;
Safety

Abstract Objective: To evaluate the feasibility, safety, and potential health benefits of an 8-week home-based neurofeedback intervention.

Design: Single-group preliminary study.

Setting: Community-based.

Participants: Nine community dwelling adults with chronic neuropathic pain, 6 women and 3 men, with an average age of 51.9 years (range, 19-78 years) and with a 7-day average minimum pain score of 4 of 10 on the visual analogue pain scale.

Interventions: A minimum of 5 neurofeedback sessions per week (40min/session) for 8 consecutive weeks was undertaken with a 12-week follow-up baseline electroencephalography recording period.

Main Outcome Measures: Primary feasibility outcomes: accessibility, tolerability, safety (adverse events and resolution), and human and information technology (IT) resources required. Secondary outcomes: pain, sensitization, catastrophization, anxiety, depression, sleep, health-related quality of life, electroencephalographic activity, and simple participant feedback.

Results: Of the 23 people screened, 11 were eligible for recruitment. One withdrew and another completed insufficient sessions for analysis, which resulted in 9 datasets analyzed. Three participants withdrew from the follow-up baselines, leaving 6 who completed the entire trial protocol. Thirteen adverse events were recorded and resolved: 1 was treatment-related, 4 were equipment-related, and 8 were administrative-related (eg, courier communication issues). The human

List of abbreviations: AE, adverse event; BPI, brief pain inventory; CNP, chronic neuropathic pain; Col, Co-investigator; CP, chronic pain; CSI, Central Sensitization Inventory; EEG, Electroencephalogram; FU, follow-up; IT, information technology; NFB, neurofeedback; NP, neuropathic pain; PI, Principal Investigator; PIP, Participant Information Pack; TP, time point; VAS (Pain), Visual Analogue Pain Scale; DASS21, Depression Anxiety and Stress Outcome Scale 21; PCS, Pain Catastrophizing Scale; PSQI, Pittsburgh Sleep Quality Index; EuroQOL-5D-5L, health related quality of life; IRAS, Integrated Research Application System; SE, standard error; P, probability.

Clinical Trial Registration No.: NCT05464199.

Cite this article as: Arch Rehabil Res Clin Transl. 2024;6:100361

<https://doi.org/10.1016/j.arrct.2024.100361>

2590-1095/© 2024 The Authors. Published by Elsevier Inc. on behalf of American Congress of Rehabilitation Medicine. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

and IT resources necessary for trial implementation were identified. There were also significant improvements in pain levels, depression, and anxiety. Six of 9 participants perceived minimal improvement or no change in symptoms after the trial, and 5 of 9 participants were satisfied with the treatment received.

Conclusions: It is feasible and safe to conduct a home-based trial of a neurofeedback intervention for people with chronic neuropathic pain, when the human and IT resources are provided and relevant governance processes are followed. Improvements in secondary outcomes merit investigation with a randomized controlled trial.

© 2024 The Authors. Published by Elsevier Inc. on behalf of American Congress of Rehabilitation Medicine. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Neuropathic pain (NP) has been defined as pain arising as a result “of a lesion or disease affecting the somatosensory system.”¹ It is frequently described as a “lancinating, shooting, electrical-like, burning, stabbing” pain,² and in contrast to many types of nociceptive pain and acute nerve injury, chronic neuropathic pain (CNP) is always dysfunctional. Accurate epidemiologic statistics for CNP are hampered by the lack of simple diagnostic criteria within the general population, and therefore, estimates of CNP prevalence vary.³ A systematic review of 21 epidemiologic studies conducted in Europe, United States, Brazil, Taiwan, and Canada reported an estimate of NP in those populations of 6.9%-10%.⁴ About 15%-25% of chronic pain (CP) is thought to be of neuropathic origin,² and the estimated prevalence of CP cases in the United Kingdom is 8.9%.⁵

Pain is considered to be chronic when it lasts or recurs for >3 to 6 months.⁶ Diagnosis of CNP is a complex physician-led process incorporating medical history, physical examination, and various tests. Standard UK treatment is pharmacological, involving close monitoring and referral to specialist pain services, depending on severity.⁷ Pharmacological treatments for CP conditions carry risks of dependence and potential misuse, which supports research into non-pharmacological options to assist in the management of CNP.

Research into a home-based self-managed intervention for central NP related to spinal cord injury suggests that neurofeedback (NFB) training may be a feasible complementary treatment option.⁸ This study builds on a previous proof of concept trial using the Axon Electroencephalogram (EEG) NFB system^a manufactured by Exsurgo Ltd for people diagnosed with general CP⁹ and aimed to assess the feasibility and safety of the same system for people diagnosed with CNP.

The primary aim of this trial was to assess the feasibility, safety, accessibility, and tolerability of this NFB intervention. Feasibility was assessed in accordance with the metrics identified by the research literature^{10,11} to investigate the important aspects of trial process, management, resources, and relevance of scientific outcomes. Safety was assessed by the number and nature of adverse events (AEs) and how effectively these were identified, managed, and resolved. AEs are defined by the Good Clinical Practice regulations as “any untoward or unintended response in a subject to whom an Investigational Medicinal Product has been administered, including occurrences which are not necessarily caused by or related to that product.”¹² AEs were recorded and collected, after consent and enrollment of participants, as required for clinical trials of all medicinal products and

devices in the United Kingdom.¹² Accessibility was defined as the proportion of all participants who subsequently entered the trial after screening relative to those who failed screening (reasons identified and recorded), in alignment with previous research.¹³

In addition, secondary outcome measures were used to identify any potential health benefits associated with this intervention and included measurement of EEG activity throughout the trial. Participants were also asked for simple feedback.

Methods

The study used a prospective, open-label, single-arm, non-randomized design and was approved by the London - Central Research Ethics Committee Health Research Authority Ethics (reference: 20/LO/0523) via the Integrated Research Application System (IRAS reference: 310674). The trial was registered with ClinicalTrials.gov (NCT05464199), and the Clinical Trials Unit of the sponsor organization, East Kent University Hospitals National Health Service Foundation Trust (reference: 2022/CTU9/NEURO).

Setting and participants

A single cohort of 11 patients was recruited via Principal Investigator (PI, MS) Out-patient clinics at East Kent Hospitals University National Health Service Foundation Trust and use of a flyer via social media (fig 1). Recruitment started in September 2022 and ended in March 2023. Table 1 details the trial eligibility criteria. Individuals who expressed interest were sent a Participant Information Pack (PIP) by email. This comprised a participant information sheet, consent form, headset measurement guide, trial flyer, and prescreening questionnaire (see [supplemental appendices](#), available online only at <http://www.archives-pmr.org/>). After review of the PIP, interested participants completed an electronic version of the prescreening questionnaire to confirm trial eligibility, provided their head circumference measurement, and confirmed their interest in proceeding to trial enrollment via an initial assessment appointment with the Co-investigator (Co-I, KS) using Zoom.^b The initial appointment comprised going through the informed consent process, completion of baseline outcome measurement questionnaires, and verification of the headset measurement provided. Subsequently,




Fig 1 Study flow diagram.

participants were enrolled into the trial, and 5 Zoom appointments were scheduled with the Co-I (KS) to complete secondary outcome measurement questionnaires at the 5 predefined follow-up (FU) time points (TPs), as per protocol (fig 2). Table 2 shows the participant demographic and clinical characteristics.

The Axon NFB device, comprising a headset and tablet (fig 3), was sent to participants via courier. Once received, all participants had 2 training sessions with the supervising researcher (CO) from the industrial partner, Exsurgo Ltd.

These sessions covered: guidance on fitting the device, orientation, usage, how to perform and complete initial EEG baselines, and all aspects of self-administering NFB training. To monitor and improve participant adherence, email reminders were sent to participants when system records showed a lack of usage, and technical support was provided when needed. All data were collected remotely and stored securely in Exsurgo's cloud-based storage service (AWS^c) using end-to-end encryption. The trial was conducted remotely at participants' homes.

Table 1 Trial inclusion and exclusion criteria.

Type of Criteria	Details
Inclusion	<ul style="list-style-type: none"> • Aged ≥ 18 y • Ongoing CNP for ≥ 3 mo • Average pain rating in the last week of $\geq 4/10$ • Head circumference 520-620 mm • Access to reliable internet connection and Wi-Fi at home
Exclusion	<ul style="list-style-type: none"> • Previous NFB training • Serious head injury (within 12 mo) • Traumatic brain injury, concussion, major neurologic disorder (eg, trigeminal neuralgia), history of seizures, psychiatric disorder • Implanted electronic neuromodulation device • Implanted pacemaker or loop recorder • Inability to provide informed consent and any change in medication or treatment planned in the 1 wk prior, during the intervention period, or in 12 wk postintervention, while EEG baselines are being recorded • Active participation in a different clinical trial

Intervention

Each baseline session commenced with patients rating their pain, mood, and sleep via the Axon application (already installed on the tablet provided to each participant), followed by 2 EEG baseline recordings: 2 minutes with eyes open followed by 2 minutes with eyes closed for week 1, completing at least 5 baselines. The NFB intervention period began in week 3 and continued for 8 weeks, involving a minimum of 5 sessions per week, each lasting 40 minutes (see fig 2). Each session commenced with an EEG eyes open baseline recording, where relative alpha, theta, and high-beta activity was recorded and averaged to calculate the threshold for each session, after which an EEG eyes closed baseline recording was performed. Each session consisted of 5×5 -minute blocks with a 1-minute rest period in between. Participants viewed a gamified representation of their brain activity as the interface for self-regulation, with the option of choosing from a selection of five “games,” for example, the jigsaw game (assembling the pieces of a randomized sequence of nature pictures), balloon game (enabling a hot air balloon to ascend from the ground into the sky), and paint game (painting a picture by numbers). After the intervention period (week 11 onward), participants continued with EEG baseline recordings for 12 weeks.

Study outcomes

Primary outcomes measured were accessibility (screening loss analysis), number of participants who completed the trial protocol, number of AEs and resolution, human resource time needed, and information technology (IT) resources required. Secondary outcomes measured were pain level and severity (assessed using the visual analog scale for pain¹⁴ VAS (Pain) and brief pain inventory [BPI]¹⁵), anxiety and depression (Depression, Anxiety and Stress Scale-21 items¹⁶), catastrophization (Pain Catastrophizing Scale¹⁷), sensitization components (Central Sensitization Inventory [CSI]¹⁸), sleep (Pittsburgh Sleep Quality Index¹⁹), health-related quality of life (EQ-5D-5L²⁰), and resting state EEG activity. Simple feedback from participants regarding perception of change during the trial and satisfaction with the treatment was obtained.

Data collection and statistical analysis

Data were collected at 6 TPs in the trial: pre-EEG baselines (Week 0, to establish a baseline before the intervention), preintervention (Week 2, to measure any potential change during the 2-week EEG baseline recording period), postintervention (Week 11, to measure and evaluate any change


**Fig 2** NFB trial intervention process diagram.

Table 2 Demographic and clinical characteristics of participants.

ID	Ethnicity	Age (y)	Sex	NP Conditions	Other Conditions	Medication, Dosage (Condition/Purpose)
EKT02	English or British	78	Female	Poststroke central nerve pain syndrome	Depression Anxiety/panic attack	Bisoprolol, 1.25 mg once a day (blood pressure) Paracetamol, 4-6 500-mg capsules once a day (pain) Clopidogrel, 75 mg once a day (blood thinner) Vitamin D, 800 IU once a day (supplement) Levothyroxine 100, 75 mg every other day (underactive thyroid) Atorvastatin, 800 mg once a day (cholesterol) Candesartan, 32 mg once a day (blood pressure) Allopurinol, 200 mg once a day (gout) Rescue herbal medicine, once a day (sleep)
EKT03	English or British	58	Female	Poststroke NP in right hemiplegic side of body	Depression	Paracetamol, 1000 mg every 6 h (pain) Fluoxetine, 20 mg once a day (low mood) Tizanidine, 2 mg twice a day (spasticity) Lercanidipine, 10 mg once a day (blood pressure) Lansoprazole, 30 mg once a day (reflux)
EKT04	English or British	19	Female	Chronic back pain and chronic headache	ADHD Migraine	Diclofenac sodium SR, 75 mg 1-2 times once a day (back pain) Melatonin, 6 mg once a day in the evening (sleep) Lansoprazole, 30 mg once a day (stomach protection) Methylphenidate hydrochloride, 54 mg in the morning and 18 mg in the evening (ADHD) Cetirizine hydrochloride, 10 mg once a day (allergy) Mometasone nasal spray, when necessary (allergy)
EKT05*	English or British	44	Female	Fibromyalgia	IBS Migraine Neck injury (including whiplash) Anxiety/panic attack Depression	Pregabalin, 200 mg 2 times once a day (CP) Etoricoxib, 120 mg once a day (fibromyalgia) Omeprazole, 20 mg 2 times once a day (IBS) Duloxetine, 30 mg once a day (fibromyalgia/pain) Paracetamol, 1200 mg every 4-6 h (headache, CP, back pain) CosmoCol, once a day (constipation) Promethazine, 25 mg once a day in the evening (sleep) Evening primrose, 3 mg once a day in the evening (hormones) Robaxin, 750 mg (back and rib pain) Sumatriptan, 50 mg (migraine)
EKT06	English or British	45	Female	Severe nerve damage in L4 and L5 Nerve, tendon, and muscle damage in C4, C5, and C6	Migraine IBS Neck injury (including whiplash) Anxiety/panic attack	Clonidine, 25 mg twice a day (menopause) Nortriptyline, 2 10-mg capsules once a day in the evening (nerve damage) Naproxen, 500 mg twice a day (anti-inflammatory) Naratriptan, 2.5 mg once a day (nerve damage) Tramadol, 50 mg 3 times a day (pain) Co-codamol, 30 mg/500 mg 2 capsules 4 times a day (pain) Sertraline, 50 mg once a day (nerve pain) Omeprazole, 20 mg twice a day (stomach protection) Sage, 100 mg once a day (vitamins and supplements) Perfectil nail, once a day (supplements)
EKT07	Mixed Ethnicity	38	Female	Nerve damage because of stroke		Gabapentin, 600 mg 3 times a day (nerve damage) Gabapentin, 2 100-mg capsules 3 times a day (nerve damage) Amitriptyline, 50 mg once a day in the evening (nerve damage) Ibuprofen gel 5%, three times a day (nerve damage) Omeprazole, 20 mg (acid reflux)
EKT08	English or British	28	Male	Disc degeneration (bulging disc at L4/L5) Spinal stenosis		

(continued)

Table 2 (Continued)

ID	Ethnicity	Age (y)	Sex	NP Conditions	Other Conditions	Medication, Dosage (Condition/Purpose)
EKT09	English or British	69	Female	Myelopathy myelitis Constant pain in lower legs and feet	Restless leg syndrome	Lansoprazole, 30 mg once a day (indigestion) Gabapentin, 2 100-mg capsules every 6 h (nerve pain) Folic acid, 5 mg once a day in the morning (blood) Amlodipine, 5 mg once a day in the morning (blood) Clopidogrel, 75 mg once a day in the morning (blood) Adcal D3, once a day in the morning (bones) Gliclazide, 40 mg once a day in the morning (diabetes) Atorvastatin, 40 mg once a day in the evening (cholesterol)
EKT10	English or British	72	Male	Cervical myelopathy C3 and C4 Central cord syndrome	IBS Neck injury (including whiplash)	Amitriptyline, 10 mg (pain) Ibuprofen gel 5% (back pain) Ibuprofen, 400 mg (pain) Co-codamol, 8/500 mg (pain)
EKT11 [†]	English or British	59	Male	High electric constant pain in the back	Neck injury (including whiplash) Anxiety/panic attack Depression Suicidal thoughts	Aspirin, 75 mg once a day Betamethasone, 10 mL 4 times a day Co-codamol, 30 mg/500 mg, 2 capsules 4 times a day Carbocisteine, 375 mg Lansoprazole, 15 mg twice a day Gabapentin, 100 mg 2 or 3 times a day
EKT12	English or British	60	Male	Poststroke central neuropathy	Anxiety/panic attack Depression	Atorvastatin, 80 mg once a day (cholesterol) Bisoprolol, 5 mg once a day (heart) Omeprazole, 20 mg once a day (stomach acid) Ramipril, 2.5 mg once a day (heart) Sertraline, 125 mg once a day (anxiety) Warfarin, 6 mg once a day (anticoagulation)

NOTE. Sample was 66.7% women and 33.3% men. Median age of women: 51.17 y (range, 19-78y); median age of men: 53.33 y (range, 28-60y). Rows highlighted in gray are the participants not included in the data analysis.

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; IBS, irritable bowel syndrome.

* Excluded because of insufficient sessions.

[†] Withdrew because of hospital admission for acute episode of back pain.




Fig 3 Axon NFB system equipment. Headset worn by individual and tablet on stand.

because of the intervention), and 3 FU TPs (Weeks 15, 19, 23, to monitor the duration and persistence of any measured changes). Because some FU data were missing, data were analyzed at 4 TPs: Weeks 0, 2, 11, and 15, which provided the most comprehensive data set to assess the intervention's immediate and short-term effect.

All data were analyzed using SPSS version 29.0,^{21,d} and descriptive statistics were used to summarize the data. Power analyses were not conducted because of the preliminary nature of the study; however, future studies should include them. To assess the effects of training sessions on different outcome measures, repeated measures analysis of variance was performed, using Bonferroni adjusted post hoc analysis for comparison between different TPs. A *P* value <.05 was considered significant.

Results

The study flow diagram (see [fig 1](#)) summarizes the screening loss analysis, and [table 2](#) presents participant demographic and clinical characteristics.

Primary outcomes

Accessibility was just below average at 48% (11/23) with the main loss of potential participants occurring after the PIP had been sent out and after the FU telephone call (see [fig 1](#)). It is possible that applicants self-screened and did not respond further after reviewing the PIP. Tolerability and acceptability were measured as 26% (6/23), with identified reasons shown in [fig 1](#). Five participants required email FU with respect to noncompliance with the number of sessions identified in the PIP. The reasons given for this included illness of a family member, complications with their own condition, hospital admission, and time shortage.

Overall safety was good with no serious AEs. There were 13 AEs in total: 1 was treatment-related, 4 were equipment-related, and 8 were related to courier deliveries. These AEs were resolved by the trial team and Exsurgo Ltd ([table 3](#)). In terms of human resources, an estimated minimum time needed for trial implementation is presented in [tables 4 and 5](#), which identify time input from Exsurgo Ltd and time input from the Co-I (KS), respectively. The total trial time estimates were 18.5 hours for Exsurgo Ltd and 77 hours for the Co-I (KS), with the latter not including appointments not attended by participants, rescheduling and booking appointments, and the administrative time required to send out PIPs, complete AE forms, and telephone participants. Time was also required from the PI (MS) on occasion to call participants to discuss a particular trial-related issue.

Secondary outcome measures

These are presented in [table 6](#) and [fig 4](#). Analysis of pain scores revealed that all participants reported improvements in total BPI scores. The mean total BPI score improved significantly from 7.0 ± 0.5 at baseline to 5.2 ± 0.8 postintervention and 5.1 ± 0.6 ($P < .05$) at FU. Total Pain Catastrophizing Scale scores improved significantly from prebaseline to post-intervention ($P < .05$) and showed continued improvements ($P < .01$) at FU (see [fig 4](#)). Clinically significant ($\geq 30\%$) improvements in BPI were reported by 5 participants. Total Depression, Anxiety and Stress Outcome Scale-21 scores significantly improved from prebaseline (31.1) to postintervention (21.3) ($P < .01$). There was an improvement in mean CSI scores, with participants mostly categorized in the mild category at the postintervention and FU. The mean CSI score decreased from 48.2 ± 6.6 to 44.0 ± 7.2 postintervention and 44.6 ± 6.7 at FU. However, there were no significant improvements in sleep or quality of life scores. Most participants (6/9) perceived minimal improvement or no change in their symptoms, and most participants (5/9) were satisfied with the treatment received. The full data analysis of the secondary outcomes measured in the trial will be published separately.

Discussion

Our objectives were to test the feasibility and safety of an 8-week home-based NFB intervention for people with CNP

and to explore if there were any potential secondary health benefits of the intervention. The composition of our sample (66.7% women and 33.3% men) reflected the research literature,⁴⁻⁶ which indicates that more women than men are diagnosed with NP. The mean age of participants was 51.9 years, which also aligns with the research literature.⁴⁻⁶ The largest source of CNP in our sample was related to pain experienced by stroke survivors (4/6 who completed the trial). In alignment with the research literature,^{4,6} most people with CNP in our sample also had associated comorbidities, including fibromyalgia and migraine. Several studies on the use of EEG NFB for various CP conditions (such as fibromyalgia, NP, and migraine) have identified a positive correlation between NFB interventions and pain improvement; however, these studies may have limitations in terms of design and sample sizes, which can potentially lead to a biased conclusion.²² Therefore, randomized controlled trials with more robust methodologies are needed to strengthen the evidence base for the use of NFB in CP management.

In terms of accessibility, this study had a 2:1 ratio for participant screening to trial enrollment and also provided insight into a range of recruitment barriers. These included participants' access to their own laptop, personal computer, or tablet (financial barrier); dependence on having an email address (an IT literacy barrier); the burden of time required from participants taking part (a 22-week trial commitment period); and the relatively high level of IT literacy required from participants. There is limited research on home-based portable EEG NFB systems, although one center-based study identified that participants often had to travel over 1 hour to the center, which caused fatigue that was counterproductive to the NFB.²³ This suggests that it would be advantageous to develop more user-friendly home-based systems, which would also minimize carbon footprint. Usability is an important concept in relation to brain-computer interface systems, and usability research studies have determined that home-based systems should be effective, simple to use, portable, and inexpensive.⁸ By doing this, the "burden of treatment" is considered to be minimized.²⁴ Technical issues might be more easily resolved if a study was center-based with IT experts on site, although having a study based in a single center would also pose geographic constraints on participant recruitment. Three participants required assistance from a family member to navigate and use the Axon system, and 1 participant had ongoing difficulties with participation because the individual was required to use their own personal IT device for the Zoom appointments, and the 2 devices she had access to (a tablet and smart mobile telephone) did not enable her to participate without difficulty. These digital barriers should be addressed in any future trial.

Logistics were improved during the trial by changing the courier delivery system so that participants were not approached by the courier requesting financial payment of a duty tax charge, which caused anxiety. Equipment-related AEs might be reduced in future trials because the equipment has already been redesigned. The treatment-related AE warrants consideration in terms of the level of concentration required during participation because this was identified as the factor associated with the symptoms reported during

Table 3 Reported AEs detailing severity and relationship to the treatment during the trial.

AE No.	PI Grade*	Treatment-Related Events	Equipment-Related Events	Admin-Related Events	Event Description†	Support and Resolution	Outcome
1	Minor	-	-	Yes	Participant received unexpected text message from courier company requesting payment of export duty charge fee prior to delivery of trial equipment, which caused anxiety. Participant emailed study team to inform them.	Study team emailed Exsurgo Ltd to request they resolve the payment issue and informed participant not to pay the charge. Exsurgo Ltd addressed the matter with the company by paying the charge.	Equipment was successfully delivered to the participant.
2	Moderate	Yes	-	-	Participant reported experiencing a heavy feeling, tingling, and weakness on her left side during the session, accompanied by fatigue. She reported that she also gets the same symptoms, localized to her left hemiplegic side, when she is anxious.	The PI telephoned the participant to discuss the issues reported. After discussion, the PI determined that the reported symptoms were associated with intense concentration and underlying anxiety issues.	Participant was reassured and wished to continue in the trial.
3	Minor	-	Yes	-	Participant reported to the PI and Col that she was unable to do the baseline sessions because the headset device was faulty.	Study team forwarded emails to Exsurgo Ltd and requested support. Exsurgo Ltd set up a support call with participant and confirmed the headset as faulty. Replacement headset sent to participant.	Participant received a new headset to resume the trial.
4	Minor	-	-	Yes	Participant received unexpected text message from courier company requesting payment of export duty charge fee prior to delivery of trial equipment, which caused anxiety. Participant emailed study team to inform them.	Study team emailed Exsurgo Ltd to request they resolve the payment issue and informed participant not to pay the charge. Exsurgo Ltd addressed the matter with the company by paying the charge.	Equipment was successfully delivered to the participant.
5	Minor	-	Yes	-	Participant's husband reported to Col that headset failed to illuminate and was unable to establish a connection with tablet, so participant was unable to do the NFB sessions.	Study team forwarded emails to Exsurgo Ltd support for awareness and resolution. Exsurgo Ltd conducted a support call with participant and found out that one electrode felt pad had fallen out.	Participants replaced the missing pad using instructions provided by Exsurgo Ltd and continued with NFB sessions.
6	Minor	-	-	Yes	Participant received unexpected text message from courier company requesting payment of export duty charge fee prior to delivery of trial equipment, which caused anxiety. Participant emailed study team to inform them.	Exsurgo Ltd addressed the matter with the company by paying the charge.	Equipment was successfully delivered to the participant.
7	Minor	-	-	Yes	Participant received an unexpected telephone call from a delivery person at the courier company, who called the participant on her mobile telephone number to inform her that they have a parcel from Exsurgo Ltd to be delivered but could not deliver it to her because the export duty charge fee had not been paid. Participant contacted PI and Col by email to inform them of the incident and to ask about what she should do.	PI apologized to the participant by email and informed her that she did not have to pay the duty import fee. PI also informed participant that the Col had raised this as an ongoing issue of concern to Exsurgo Ltd and had requested that Exsurgo Ltd stop the courier from sending inappropriate text messages and contacting participants inappropriately in this manner. Exsurgo Ltd addressed the matter with the company by paying the charge.	Equipment was successfully delivered to the participant.

(continued)

Table 3 (Continued)

AE No.	PI Grade*	Treatment-Related Events	Equipment-Related Events	Admin-Related Events	Event Description [†]	Support and Resolution	Outcome
8	Minor	-	-	Yes	Participant emailed Col to report that she had received a letter and telephone call from the courier company informing her that the export duty charge fee for the trial equipment had not been paid. The letter stated that if Exsurgo Ltd can send the courier company a letter or email saying that they will pay the money, then her name would be taken off their list.	The Col sent an email back to the participant, copied to the PI and Exsurgo Ltd, to enable both to be made aware of this and enable investigation and resolution by Exsurgo Ltd. Exsurgo Ltd addressed the matter with the company by paying the charge.	Equipment was successfully delivered to the participant.
9	Minor	-	-	Yes	Participant reported to Col that one of the headset electrode pads kept falling out, which meant that she could not do her baseline EEG recordings.	Study team emailed Exsurgo Ltd to inform them of the issue. Exsurgo Ltd sent a new electrode pad with replacement instructions to the participant.	Participant replaced electrode pad and continued with the trial.
10	Minor	-	-	Yes	Participant reported to Col that the headset was not working.	Col replied by email and copied Exsurgo Ltd support to request support for the participant. Participant sent screenshots of the app to Exsurgo Ltd support. Exsurgo Ltd support informed the participant that the Axon app had failed to install on the tablet and sent further technical advice.	Participant followed Exsurgo Ltd advice and informed study team that the equipment was working again.
11	Minor	-	Yes	-	Participant informed that the headset was not working, which prevented her from progressing beyond the eyes open baseline recordings.	Exsurgo Ltd arranged delivery of the new headset device and extended the training period by 1 more week to take delivery period into account.	Participant received a new headset device and continued with the trial.
12	Minor	-	-	Yes	Participant reported one of the headset electrode pads had fallen out.	Study team emailed Exsurgo Ltd to inform them of the issue. Exsurgo Ltd sent a new electrode pad with replacement instructions to the participant.	Participant replaced electrode pad and continued with the trial.
13	Minor	-	Yes	-	Participant reported a joint on the headset seemed to be broken and was not recording EEG activity properly.	Exsurgo Ltd arranged for delivery of a new headset.	Participant received new headset and continued with the trial.

* PI grading of AEs as minor, moderate, or serious.

† Event description includes relationship to participation in the trial and treatment.

Table 4 Resource metric measurement - training time for participants from Exurgo Ltd.

Participant	Number of Training Sessions*	Total Time in Training and Support Sessions (min)
EK02	2	100
EK03	2	100
EK04	2	100
EK06	2	100
EK07	2	300 ⁱ
EK08	2	100
EK09	2	100
EK10	2	100
EK12	2	100

NOTE. Total time training and supporting participants = 18.5 h.

* Training was split into 2 sessions – fitting and baseline, followed by NFB training during the transition week.

ⁱ Participant required a lot of support and had very high anxiety throughout.

intervention use. Further details on AE outcomes is presented in [table 3](#).

Three participants dropped out during the FU period of 12 weeks (see [fig 1](#)), which was considered by some to be too long. The length of the FU period was designed to assess the sustainability of NFB treatment effects and would benefit from adjustment in future trials as appropriate. At least 2 participants informed the Co-I (KS) and PI (MS) that they did not know that they should be performing baseline readings for 12 weeks during the FU time period, which may be related to memory issues and the complexity of the participation process. In any future trial, these tolerability issues should be addressed.

In terms of human resources, it would be possible to improve the efficiency of the process and reduce the time burden on the research team with some improvements to the software system used; for example, an automatic email alert sent to the PI (MS) and Co-I (KS) to inform them of when a participant has completed the electronic screening form. Improvements in pain levels, mood, and central sensitization scores were detected, which indicates that these outcome measures used are sensitive and relevant for use in a larger potential future trial. These outcomes and learning insights provide a solid foundation for future trials.

Study limitations

Our results are not generalizable to the larger population of people living with CNP, given the small sample and unblinded single-group design. This was also a convenience sample, which is not representative of the larger population of people living with CNP. The study experienced a notable dropout rate, technical issues, and limited perceived benefits among participants. Our eligibility criteria and screening protocol were also subject to selection bias. Secondary outcome results should be interpreted with caution because of the small sample size. These limitations will be addressed by a larger randomized controlled trial.

Conclusions

It is feasible and safe to conduct a home-based NFB intervention for people with CNP within the National Health Service framework, when the identified human and IT resources are provided and relevant governance processes are followed. The improvements in the secondary outcomes of pain and mood justify further investigation with a

Table 5 Resource metric measurement – appointment time with the Co-I.

Number of Participants	Total Number of Zoom Video Appointments per Participant in the Trial	Time (h) for First Zoom Video Assessment Appointment	Total Time (h) for 5 FU Zoom Video Appointments of 1 h	Total Appointment Time in Trial to Support Participants (h)
11	6	2	5	77

NOTE. The time related to appointment nonattendance by participants, appointment rescheduling, and administrative tasks to support the trial are not included.

Table 6 Overall mean outcome measurement scores.

Outcome Measurements	Prebaseline (n=9)	Preintervention (n=9)	Postintervention (n=9)	FU 1 (n=9)
Overall BPI	7.0±0.5	6.6±0.6	5.2±0.8	5.1±0.6
DASS-21	31.1±5.3	27.7±6.6	21.3±5.4	22.0±4.7
PCS	28.7±4.8	21.7±4.6	20.4±5.4	17.9±5.0
CSI	48.2±6.6	47.3±6.6	44.0±7.3	44.6±6.7
PSQI	10.4±1.5	10.7±2.2	10.9±2.0	9.6±1.6
EQ-5D-5L (VAS)	52.2±6.3	45.7±6.8	52.0±7.4	51.1±6.0

NOTE. Data are shown as overall mean ± SE scores of the trial participants.

Abbreviations: DASS-21, Depression, Anxiety and Stress Scale-21 items; PCS, Pain Catastrophizing Score; PSQI, Pittsburgh Sleep Quality Index.




Fig 4 Secondary outcome measurement scores at 4 TPs in the trial. This figure corresponds to the overall mean scores of the trial participants for (A) Overall BPI, (B) DASS-21, (C) PCS, and (D) CSI-A. The bar graphs are represented as mean \pm SE where * denotes $P < .05$ and ** denotes $P < .01$. DASS-21, Depression, Anxiety and Stress Scale-21 items; PCS, Pain Catastrophizing Scale.

randomized controlled trial to confirm the efficacy of the intervention.

Suppliers

- Axon EEG NFB system; Exsurgo Ltd.
- Zoom communications platform; Zoom Video Communications, Inc.
- AWS cloud-based storage service; Amazon.
- SPSS, version 29.0; IBM.

Corresponding author

Karen Saunders, BSc (Hons), Centre for Health Services Studies, University of Kent, Canterbury, Kent, CT2 7NP U.K. *E-mail address:* kss31@kent.ac.uk.

Disclosures

The investigators have no financial or nonfinancial disclosures to make in relation to this project.

Acknowledgments

We thank all participants for their valuable time and effort; this study would not have been possible without them.

References

- International Association for the Study of Pain. What is neuropathic pain? Available at: <https://www.iasp-pain.org/wp-content/uploads/2022/10/What-is-Neuropathic-Pain.pdf> Accessed August, 2024.
- Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. *Lancet* 2021;397:2082-97. [https://doi.org/10.1016/S0140-6736\(21\)00393-7](https://doi.org/10.1016/S0140-6736(21)00393-7).

3. Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. *Nat Rev Dis Primers* 2017;3:17002. <https://doi.org/10.1038/nrdp.2017.2>.
4. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. *Pain* 2014;155:654-62.
5. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. *BMJ Open* 2016;6:e010364. <https://doi.org/10.1136/bmjopen-2015-010364>.
6. Merskey H, Bogduk N. Classification of Chronic Pain. IASP Task Force on Taxonomy. 2nd ed. Seattle: IASP Press; 1994.
7. National Institute for Health and Care Excellence (NICE). Neuropathic Pain - drug treatment. Last revised February 2024. Available at: <https://cks.nice.org.uk/topics/neuropathic-pain-drug-treatment/> Accessed August, 2024.
8. Al-Taleb MKH, Purcell M, Fraser M, Petric-Gray N, Vuckovic A. Home used, patient self-managed, brain-computer interface for the management of central neuropathic pain post spinal cord injury: usability study. *J Neuroeng Rehabil* 2019;16:128.
9. Birch N, Graham J, Ozolins C, Kumarasinghe K, Almesfer F. Home-based EEG neurofeedback intervention for the management of chronic pain. *Front Pain Res (Lausanne)* 2022;3:855493. <https://doi.org/10.3389/fpain.2022.855493>.
10. Learmonth YC, Motl RW. Important considerations for feasibility studies in physical activity research involving persons with multiple sclerosis: a scoping systematic review and case study. *Pilot Feasibility Stud* 2017;4:1.
11. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. *BMC Med Res Methodol* 2010;10:1.
12. Good Clinical Practice (GCP). Available at: <https://www.nih.ac.uk/health-and-care-professionals/training/good-clinical-practice.htm>. Accessed October 2023
13. Kozłowski AJ, Fabian M, Lad D, Delgado AD. Feasibility and safety of a powered exoskeleton for assisted walking for persons with multiple sclerosis: a single-group preliminary study. *Arch Phys Med Rehab* 2017;98:1300-7.
14. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). *Arthritis Care Res (Hoboken)* 2011;63(Suppl 11):S240-52.
15. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singap* 1994;23:129-38.
16. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. *Br J Clin Psychol* 2005;44(Pt 2):227-39.
17. Pain Catastrophizing Scale. Physiopedia. Available at: https://www.physio-pedia.com/Pain_Catastrophizing_Scale. Accessed November 2023.
18. Teater M, Teater D. The Central Sensitization Inventory (CSI). Available at: https://www.emdr-training.net/wp-content/uploads/2019/09/CSI_Inventory_and_Scoring.pdf. Accessed December 2023.
19. Buysse DJ, Reynolds 3rd CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193-213.
20. Balestroni G, Bertolotti G. [EuroQol-5D (EQ-5D): an instrument for measuring quality of life] [Italian]. *Monaldi Arch Chest Dis* 2012;78:155-9.
21. IBM SPSS Statistics. Version 29. 2023.
22. Diotaiuti P, Corrado S, Tosti B, et al. Evaluating the effectiveness of neurofeedback in chronic pain management: a narrative review. *Front Psychol* 2024;15:1369487.
23. Hassan MA, Fraser M, Conway BA, Allan DB, Vuckovic A. The mechanism of neurofeedback training for treatment of central neuropathic pain in paraplegia: a pilot study. *BMC Neurol* 2015;15:200.
24. Gonçalves AV, Jácome CI, Demain SH, Hunt KJ, Marques AS. Burden of treatment in the light of the international classification of functioning, disability and health: a "best fit" framework synthesis. *Disabil Rehabil* 2017;39:1253-61.